Literature DB >> 19384928

Membrane technology for purification of therapeutic proteins.

Andrew L Zydney1.   

Abstract

Membrane systems are used throughout the downstream purification in the commercial production of high value therapeutic proteins. Over the last two decades, new membranes, modules, and systems have been developed specifically to meet the requirements of the biotechnology industry. These developments have been facilitated by an improved fundamental understanding of: (1) the effects of electrostatic interactions and concentration polarization on protein transmission during ultrafiltration and (2) the role of membrane morphology on protein fouling during both sterile and virus filtration. This perspective highlights some of the key work in this area and provides insights into possible future improvements in membrane technology for the purification of recombinant therapeutic proteins. Copyright 2009 Wiley Periodicals, Inc.

Mesh:

Substances:

Year:  2009        PMID: 19384928     DOI: 10.1002/bit.22308

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  5 in total

1.  Electrophoretic transport of biomolecules through carbon nanotube membranes.

Authors:  Xinghua Sun; Xin Su; Ji Wu; Bruce J Hinds
Journal:  Langmuir       Date:  2011-02-21       Impact factor: 3.882

2.  Analysis of fouling and breakthrough of process related impurities during depth filtration using confocal microscopy.

Authors:  Maria Parau; Thomas F Johnson; James Pullen; Daniel G Bracewell
Journal:  Biotechnol Prog       Date:  2022-01-26

3.  Evaluation of novel large cut-off ultrafiltration membranes for adenovirus serotype 5 (Ad5) concentration.

Authors:  Piergiuseppe Nestola; Duarte L Martins; Cristina Peixoto; Susanne Roederstein; Tobias Schleuss; Paula M Alves; José P B Mota; Manuel J T Carrondo
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

4.  Synthesis and analysis of separation networks for the recovery of intracellular chemicals generated from microbial-based conversions.

Authors:  Kirti M Yenkie; Wenzhao Wu; Christos T Maravelias
Journal:  Biotechnol Biofuels       Date:  2017-05-08       Impact factor: 6.040

5.  Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.

Authors:  Franziska Schandock; Camilla Frich Riber; Annika Röcker; Janis A Müller; Mirja Harms; Paulina Gajda; Kaja Zuwala; Anna H F Andersen; Kaja Borup Løvschall; Martin Tolstrup; Florian Kreppel; Jan Münch; Alexander N Zelikin
Journal:  Adv Healthc Mater       Date:  2017-09-25       Impact factor: 9.933

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.